JPWO2020033955A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020033955A5 JPWO2020033955A5 JP2021531626A JP2021531626A JPWO2020033955A5 JP WO2020033955 A5 JPWO2020033955 A5 JP WO2020033955A5 JP 2021531626 A JP2021531626 A JP 2021531626A JP 2021531626 A JP2021531626 A JP 2021531626A JP WO2020033955 A5 JPWO2020033955 A5 JP WO2020033955A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- cycloalkyl
- formula
- pruritus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 61
- 208000003251 Pruritus Diseases 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 29
- 206010047642 Vitiligo Diseases 0.000 claims 26
- 229910052799 carbon Inorganic materials 0.000 claims 24
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 230000001363 autoimmune Effects 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 14
- 230000001684 chronic Effects 0.000 claims 12
- 206010016654 Fibrosis Diseases 0.000 claims 11
- 230000004761 fibrosis Effects 0.000 claims 11
- 201000004384 alopecia Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 231100000360 alopecia Toxicity 0.000 claims 9
- 208000003476 Primary Myelofibrosis Diseases 0.000 claims 8
- 208000006641 Skin Disease Diseases 0.000 claims 8
- 150000001602 bicycloalkyls Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 230000001404 mediated Effects 0.000 claims 8
- 206010000496 Acne Diseases 0.000 claims 7
- 206010025135 Lupus erythematosus Diseases 0.000 claims 7
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 206010025310 Other lymphomas Diseases 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 201000010874 syndrome Diseases 0.000 claims 7
- 208000006673 Asthma Diseases 0.000 claims 6
- 206010003816 Autoimmune disease Diseases 0.000 claims 6
- 208000001083 Kidney Disease Diseases 0.000 claims 6
- 206010028537 Myelofibrosis Diseases 0.000 claims 6
- 206010029149 Nephropathy Diseases 0.000 claims 6
- 206010029151 Nephropathy Diseases 0.000 claims 6
- 230000037390 scarring Effects 0.000 claims 6
- 206010012601 Diabetes mellitus Diseases 0.000 claims 5
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 230000002757 inflammatory Effects 0.000 claims 5
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 5
- 230000003448 neutrophilic Effects 0.000 claims 5
- 201000004681 psoriasis Diseases 0.000 claims 5
- 206010003246 Arthritis Diseases 0.000 claims 4
- 206010003645 Atopy Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 4
- 206010024324 Leukaemias Diseases 0.000 claims 4
- 206010033775 Paraesthesia Diseases 0.000 claims 4
- 206010046736 Urticarias Diseases 0.000 claims 4
- 206010047115 Vasculitis Diseases 0.000 claims 4
- 230000001154 acute Effects 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 200000000018 inflammatory disease Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 108009000283 Allograft Rejection Proteins 0.000 claims 3
- 206010068168 Androgenetic alopecia Diseases 0.000 claims 3
- 208000010247 Contact Dermatitis Diseases 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 3
- 241000238631 Hexapoda Species 0.000 claims 3
- 208000002557 Hidradenitis Diseases 0.000 claims 3
- 206010020243 Hodgkin's disease Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 102100008902 ITK Human genes 0.000 claims 3
- 102100019518 JAK3 Human genes 0.000 claims 3
- 101700007593 JAK3 Proteins 0.000 claims 3
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 3
- 210000004185 Liver Anatomy 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000008696 Polycythemia Vera Diseases 0.000 claims 3
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims 3
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 201000002996 androgenic alopecia Diseases 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 3
- 231100000080 dermatitis contact Toxicity 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 230000003176 fibrotic Effects 0.000 claims 3
- 230000002496 gastric Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 230000035935 pregnancy Effects 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 206010063409 Acarodermatitis Diseases 0.000 claims 2
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 2
- 206010069351 Acute lung injury Diseases 0.000 claims 2
- 206010001767 Alopecia universalis Diseases 0.000 claims 2
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 claims 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 2
- 206010003885 Azotaemia Diseases 0.000 claims 2
- 210000000013 Bile Ducts Anatomy 0.000 claims 2
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010006451 Bronchitis Diseases 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 206010009887 Colitis Diseases 0.000 claims 2
- 208000002573 Connective Tissue Disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010014910 Enthesopathy Diseases 0.000 claims 2
- 208000002047 Essential Thrombocythemia Diseases 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010018651 Graft versus host disease Diseases 0.000 claims 2
- 210000004209 Hair Anatomy 0.000 claims 2
- 210000003128 Head Anatomy 0.000 claims 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 2
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims 2
- 208000002260 Keloid Diseases 0.000 claims 2
- 210000001117 Keloid Anatomy 0.000 claims 2
- 210000003734 Kidney Anatomy 0.000 claims 2
- 208000000214 Leukemia, Myelomonocytic, Chronic Diseases 0.000 claims 2
- 208000009874 Lice Infestations Diseases 0.000 claims 2
- 208000002780 Macular Degeneration Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010028576 Myeloproliferative disease Diseases 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 206010058105 Neutrophilic dermatosis Diseases 0.000 claims 2
- 229960001592 Paclitaxel Drugs 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 claims 2
- 206010034606 Peripheral neuropathy Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000009954 Pyoderma Gangrenosum Diseases 0.000 claims 2
- 206010037844 Rash Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000005687 Scabies Diseases 0.000 claims 2
- 241000447727 Scabies Species 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 210000003491 Skin Anatomy 0.000 claims 2
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 2
- 208000010265 Sweet Syndrome Diseases 0.000 claims 2
- 206010043709 Thyroid disease Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 208000009852 Uremia Diseases 0.000 claims 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 201000004624 dermatitis Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 201000008808 fibrosarcoma Diseases 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 2
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims 2
- 201000004044 liver cirrhosis Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000002481 myositis Diseases 0.000 claims 2
- 201000005737 orchitis Diseases 0.000 claims 2
- 210000000056 organs Anatomy 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 2
- 230000001823 pruritic Effects 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 201000008736 systemic mastocytosis Diseases 0.000 claims 2
- 201000009594 systemic scleroderma Diseases 0.000 claims 2
- 229930003347 taxol Natural products 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- -1 5-((3R,5R)-1,1-difluorospiro[2.4]heptan-5-yl)-7H-pyrrolo[2,3-d]pyrimidine Chemical compound 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010000503 Acne cystic Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000005298 Acute Pain Diseases 0.000 claims 1
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000004304 Addison's disease Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000002496 Adult-Onset Still's Disease Diseases 0.000 claims 1
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 1
- 206010048594 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000004631 Alopecia Areata Diseases 0.000 claims 1
- 206010001766 Alopecia totalis Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 208000003455 Anaphylaxis Diseases 0.000 claims 1
- 208000007502 Anemia Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 206010060963 Arterial disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003230 Arteritis Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 206010003402 Arthropod sting Diseases 0.000 claims 1
- 208000000104 Arthus Reaction Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 1
- 229950002916 Avelumab Drugs 0.000 claims 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 1
- 206010060945 Bacterial infection Diseases 0.000 claims 1
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 208000009137 Behcet Syndrome Diseases 0.000 claims 1
- 201000008335 Behcet's disease Diseases 0.000 claims 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 1
- 208000003432 Bone Disease Diseases 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims 1
- JQGKRVBGJDIOSH-SWLSCSKDSA-N C1(CC1)CC1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C Chemical compound C1(CC1)CC1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C JQGKRVBGJDIOSH-SWLSCSKDSA-N 0.000 claims 1
- PWLBOGZWJVTIRY-GXTWGEPZSA-N C1(CCC1)C(=O)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C Chemical compound C1(CCC1)C(=O)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C PWLBOGZWJVTIRY-GXTWGEPZSA-N 0.000 claims 1
- 206010073960 CANDLE syndrome Diseases 0.000 claims 1
- 101700048476 CR23 Proteins 0.000 claims 1
- 101700007059 CR33 Proteins 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 206010062746 Carditis Diseases 0.000 claims 1
- 208000005024 Castleman Disease Diseases 0.000 claims 1
- 210000003679 Cervix Uteri Anatomy 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010008943 Chronic leukaemia Diseases 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 206010009839 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 206010010428 Congenital cystic kidney disease Diseases 0.000 claims 1
- 206010056489 Coronary artery restenosis Diseases 0.000 claims 1
- 206010070976 Craniocerebral injury Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 208000001591 Cryopyrin-Associated Periodic Syndrome Diseases 0.000 claims 1
- 208000009267 Cystic Kidney Disease Diseases 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 208000001840 Dandruff Diseases 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003024 Diffuse alopecia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 206010013687 Drug eruption Diseases 0.000 claims 1
- 208000000718 Duodenal Ulcer Diseases 0.000 claims 1
- 229950009791 Durvalumab Drugs 0.000 claims 1
- 208000005679 Eczema Diseases 0.000 claims 1
- 206010014599 Encephalitis Diseases 0.000 claims 1
- 206010014698 Endocrine disease Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010052834 Eosinophilic pustular folliculitis Diseases 0.000 claims 1
- 206010015084 Episcleritis Diseases 0.000 claims 1
- 229960001433 Erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 210000003743 Erythrocytes Anatomy 0.000 claims 1
- 208000006881 Esophagitis Diseases 0.000 claims 1
- 210000003238 Esophagus Anatomy 0.000 claims 1
- 231100000776 Exotoxin Toxicity 0.000 claims 1
- 208000009745 Eye Disease Diseases 0.000 claims 1
- 210000004709 Eyebrows Anatomy 0.000 claims 1
- UVMRUUAXXSEKBU-HFZMZTSTSA-N FC1(C[C@]11C[C@H](CC1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C)F Chemical compound FC1(C[C@]11C[C@H](CC1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C)F UVMRUUAXXSEKBU-HFZMZTSTSA-N 0.000 claims 1
- JOOXGONBYJJLOS-DYEKYZERSA-N FC1([C@@H](C1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)CC)F Chemical compound FC1([C@@H](C1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)CC)F JOOXGONBYJJLOS-DYEKYZERSA-N 0.000 claims 1
- WGWWIVYXVXQCLC-IACUBPJLSA-N FC1([C@@H](C1)CC1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C)F Chemical compound FC1([C@@H](C1)CC1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C)F WGWWIVYXVXQCLC-IACUBPJLSA-N 0.000 claims 1
- KULMFWJHZABAFA-DMDPSCGWSA-N FC1([C@H](C1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C)F Chemical compound FC1([C@H](C1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C)F KULMFWJHZABAFA-DMDPSCGWSA-N 0.000 claims 1
- KWYNRYCEOIQZBK-HZLRFILRSA-N FC1([C@H](C1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(\C=C\CN(C)C)=O)C)F Chemical compound FC1([C@H](C1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(\C=C\CN(C)C)=O)C)F KWYNRYCEOIQZBK-HZLRFILRSA-N 0.000 claims 1
- BMTKJPSVZZUNBN-CFVMTHIKSA-N FC1([C@H](C1)C1=CNC=2N=CN=C(C=21)N[C@H]1CC[C@H](N(C1)C(C=C)=O)C(C)C)F Chemical compound FC1([C@H](C1)C1=CNC=2N=CN=C(C=21)N[C@H]1CC[C@H](N(C1)C(C=C)=O)C(C)C)F BMTKJPSVZZUNBN-CFVMTHIKSA-N 0.000 claims 1
- 206010016207 Familial mediterranean fever Diseases 0.000 claims 1
- 208000007659 Fibroadenoma Diseases 0.000 claims 1
- 206010016629 Fibroma Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010016766 Flatulence Diseases 0.000 claims 1
- 208000003228 Foreign Body Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010058872 Fungal sepsis Diseases 0.000 claims 1
- 210000000232 Gallbladder Anatomy 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010017860 Gastritis atrophic Diseases 0.000 claims 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 208000007465 Giant Cell Arteritis Diseases 0.000 claims 1
- 208000007565 Gingivitis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010051920 Glomerulonephropathy Diseases 0.000 claims 1
- 206010061989 Glomerulosclerosis Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 1
- 206010070737 HIV associated nephropathy Diseases 0.000 claims 1
- 206010061187 Haematopoietic neoplasm Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 206010019641 Hepatic cirrhosis Diseases 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 208000006454 Hepatitis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 206010019939 Herpes gestationis Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010058490 Hyperoxia Diseases 0.000 claims 1
- 206010020718 Hyperplasia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 241000248486 Hypotrichia Species 0.000 claims 1
- 229960000908 Idarubicin Drugs 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 claims 1
- 208000002370 Immune Complex Disease Diseases 0.000 claims 1
- 206010021857 Infection parasitic Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010061217 Infestation Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000006897 Interstitial Lung Disease Diseases 0.000 claims 1
- 210000000936 Intestines Anatomy 0.000 claims 1
- 208000001024 Intrahepatic Cholestasis Diseases 0.000 claims 1
- 206010022972 Iron deficiency anaemia Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 208000003377 Juvenile-onset scleroderma Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 206010023332 Keratitis Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 206010023365 Keratopathy Diseases 0.000 claims 1
- 206010048649 Koebner phenomenon Diseases 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 210000000867 Larynx Anatomy 0.000 claims 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 208000007820 Lichen Sclerosus et Atrophicus Diseases 0.000 claims 1
- 206010024434 Lichen sclerosus Diseases 0.000 claims 1
- 206010024515 Linear IgA disease Diseases 0.000 claims 1
- 208000006132 Lipodystrophy Diseases 0.000 claims 1
- 206010024606 Lipodystrophy Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010025169 Lyme disease Diseases 0.000 claims 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 claims 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 1
- 208000008585 Mastocytosis Diseases 0.000 claims 1
- 208000002805 Mediastinal Fibrosis Diseases 0.000 claims 1
- 206010027183 Meniere's disease Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010054949 Metaplasia Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 claims 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 210000003739 Neck Anatomy 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 108009000551 Nephrotic syndrome Proteins 0.000 claims 1
- 208000009025 Nervous System Disease Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 208000004296 Neuralgia Diseases 0.000 claims 1
- 208000007538 Neurilemmoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 208000006883 Neuromuscular Disease Diseases 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 108010019706 Nivolumab Proteins 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- DNHWQEMJLPZUQI-QWHCGFSZSA-N OC1(CCC1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C Chemical compound OC1(CCC1)C1=CNC=2N=CN=C(C=21)N[C@@H]1CC[C@@H](N(C1)C(C=C)=O)C DNHWQEMJLPZUQI-QWHCGFSZSA-N 0.000 claims 1
- 229940005483 OPIOID ANALGESICS Drugs 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 210000003300 Oropharynx Anatomy 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 206010033165 Ovarian failure Diseases 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000008664 Papular urticaria Diseases 0.000 claims 1
- 206010033733 Papule Diseases 0.000 claims 1
- 208000006551 Parasitic Disease Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 241000517324 Pediculidae Species 0.000 claims 1
- 241000517307 Pediculus humanus Species 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 206010034674 Peritonitis Diseases 0.000 claims 1
- 206010034695 Pernicious anaemia Diseases 0.000 claims 1
- 206010034754 Petechiae Diseases 0.000 claims 1
- 210000003800 Pharynx Anatomy 0.000 claims 1
- 241001674048 Phthiraptera Species 0.000 claims 1
- 208000009901 Polycystic Kidney Disease Diseases 0.000 claims 1
- 208000005987 Polymyositis Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000001818 Pseudofolliculitis Barbae Diseases 0.000 claims 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037175 Psychiatric disease Diseases 0.000 claims 1
- 210000003324 RBC Anatomy 0.000 claims 1
- 206010037876 Rash papular Diseases 0.000 claims 1
- 208000002574 Reactive Arthritis Diseases 0.000 claims 1
- 210000000664 Rectum Anatomy 0.000 claims 1
- 206010038294 Reiter's syndrome Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010038444 Renal failure chronic Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 210000001525 Retina Anatomy 0.000 claims 1
- 206010038932 Retinopathy Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010039083 Rhinitis Diseases 0.000 claims 1
- 206010039580 Scar Diseases 0.000 claims 1
- 206010039667 Schwannoma Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000008742 Seborrheic Dermatitis Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 206010053879 Sepsis syndrome Diseases 0.000 claims 1
- 206010040070 Septic shock Diseases 0.000 claims 1
- 206010040400 Serum sickness Diseases 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 208000006045 Spondylarthropathy Diseases 0.000 claims 1
- 206010052775 Spondyloarthropathy Diseases 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000005482 Systemic Juvenile Rheumatoid Arthritis Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 206010043207 Temporal arteritis Diseases 0.000 claims 1
- 208000001608 Teratocarcinoma Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 210000001550 Testis Anatomy 0.000 claims 1
- 210000001685 Thyroid Gland Anatomy 0.000 claims 1
- 206010043866 Tinea capitis Diseases 0.000 claims 1
- 210000003371 Toes Anatomy 0.000 claims 1
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 229950007217 Tremelimumab Drugs 0.000 claims 1
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 206010045240 Type I hypersensitivity Diseases 0.000 claims 1
- 206010054000 Type II hypersensitivity Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 206010046750 Urticaria papular Diseases 0.000 claims 1
- 210000004291 Uterus Anatomy 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 229960004528 Vincristine Drugs 0.000 claims 1
- 206010047461 Viral infection Diseases 0.000 claims 1
- 208000001756 Virus Disease Diseases 0.000 claims 1
- 206010057295 Vocal cord inflammation Diseases 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 Vorinostat Drugs 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 206010048222 Xerosis Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000001476 alcoholic Effects 0.000 claims 1
- 230000000172 allergic Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 230000002491 angiogenic Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 108010072668 atezolizumab Proteins 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 230000003143 atherosclerotic Effects 0.000 claims 1
- 230000001746 atrial Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 108010010826 avelumab Proteins 0.000 claims 1
- 201000008975 bone inflammation disease Diseases 0.000 claims 1
- 201000010816 bone resorption disease Diseases 0.000 claims 1
- 201000003149 breast fibroadenoma Diseases 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 201000001084 cerebrovascular disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000006082 chickenpox Diseases 0.000 claims 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 201000000522 chronic kidney disease Diseases 0.000 claims 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 210000002777 columnar cell Anatomy 0.000 claims 1
- 201000000054 coronary restenosis Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 201000003883 cystic fibrosis Diseases 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 231100000406 dermatitis Toxicity 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 108010016436 durvalumab Proteins 0.000 claims 1
- 231100001003 eczema Toxicity 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 201000001561 eosinophilic gastritis Diseases 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 239000002095 exotoxin Substances 0.000 claims 1
- 201000009846 fatty liver disease Diseases 0.000 claims 1
- 230000002344 fibroplastic Effects 0.000 claims 1
- 201000005160 follicular thyroid carcinoma Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 201000002146 gastrointestinal system disease Diseases 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 201000010915 glioblastoma multiforme Diseases 0.000 claims 1
- 201000005569 gout Diseases 0.000 claims 1
- 201000010912 granulomatous dermatitis Diseases 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000002489 hematologic Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000002949 hemolytic Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000000222 hyperoxic Effects 0.000 claims 1
- 201000002980 hyperparathyroidism Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 201000009495 hypotrichosis Diseases 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000000968 intestinal Effects 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000001418 larval Effects 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 201000009906 meningitis Diseases 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 230000015689 metaplastic ossification Effects 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 201000005962 mycosis fungoide Diseases 0.000 claims 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000002988 nephrogenic Effects 0.000 claims 1
- 230000001537 neural Effects 0.000 claims 1
- 201000009053 neurodermatitis Diseases 0.000 claims 1
- 230000005015 neuronal process Effects 0.000 claims 1
- 230000002981 neuropathic Effects 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 1
- 201000002674 obstructive nephropathy Diseases 0.000 claims 1
- 230000003364 opioid Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 231100000539 ovarian failure Toxicity 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 201000008743 palmoplantar keratosis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000024241 parasitism Effects 0.000 claims 1
- 230000001936 parietal Effects 0.000 claims 1
- 108010026276 pembrolizumab Proteins 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 201000011152 pemphigus Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 230000000737 periodic Effects 0.000 claims 1
- 230000002085 persistent Effects 0.000 claims 1
- 201000010115 photosensitivity disease Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000000750 progressive Effects 0.000 claims 1
- LVOICKNPHXSSQM-UHFFFAOYSA-N prop-2-en-1-one Chemical compound C=C[C]=O LVOICKNPHXSSQM-UHFFFAOYSA-N 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 201000001263 psoriatic arthritis Diseases 0.000 claims 1
- 230000001107 psychogenic Effects 0.000 claims 1
- 230000002685 pulmonary Effects 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 200000000008 restenosis Diseases 0.000 claims 1
- 201000001949 retinal vasculitis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 230000001235 sensitizing Effects 0.000 claims 1
- 230000001953 sensory Effects 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 201000001297 telogen effluvium Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 200000000020 tissue injury Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 108010072993 tremelimumab Proteins 0.000 claims 1
- 230000009959 type I hypersensitivity Effects 0.000 claims 1
- 230000008026 type II hypersensitivity Effects 0.000 claims 1
- 230000028063 type III hypersensitivity Effects 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 230000017613 viral reproduction Effects 0.000 claims 1
- 200000000019 wound Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 201000006083 xeroderma pigmentosum Diseases 0.000 claims 1
- 231100001002 xerosis Toxicity 0.000 claims 1
Description
(実施例16)
イソブチル4-(((3R,6S)-1-アクリロイル-6-メチルピペリジン-3-イル)アミノ)-7H-ピロロ[2,3-d]ピリミジン-5-カルボキシレートの調製
Preparation of isobutyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
スキーム17.イソブチル4-(((3R,6S)-1-アクリロイル-6-メチルピペリジン-3-イル)アミノ)-7H-ピロロ[2,3-d]ピリミジン-5-カルボキシレートの調製
(実施例17)
1-((2S,5R)-5-((5-(シクロブタンカルボニル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-メチルピペリジン-1-イル)プロパ-2-エン-1-オンの調製
1-((2S,5R)-5-((5-(cyclobutanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)propa- Preparation of 2-en-1-one
(実施例22)
(R)-1-(3-((5-(シクロペンチルメチル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)ピペリジン-1-イル)プロパ-2-エン-1-オンの調製
(R)-1-(3-((5-(cyclopentylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-ene-1- On preparation
スキーム23.(R)-1-(3-((5-(シクロペンチルメチル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)ピペリジン-1-イル)プロパ-2-エン-1-オンの調製
Claims (31)
(式中、
Xは、NまたはCR3であり、
nは、0、1または2であり、
mは、0、1または2であり、
R1は、COOR6、C1-C5アルキル-COOR6、ビシクロアルキル、C1-C5-アルキル-ヘテロシクリル、C1-C5-アルキル-C3-C6-シクロアルキル、C3-C6シクロアルキル、C(O)C1-C5アルキル、C(O)C3-C6シクロアルキル、C(O)C3-C6ヘテロシクリルから選択され、
シクロアルキル、ビシクロアルキル、ヘテロシクリル、およびアルキルは、C1-C5アルキル、C1-C5アルコキシ、C1-C5アルキル-C1-C5アルコキシ、CN、ハロゲン、COOR6、またはC1-C5-アルキル-COOR6から選択される1つまたは複数の基で置換されていてもよく、
R2は、H、C1-C5アルキル、C3-C6シクロアルキル、C1-C5-アルキル-C3-C6-シクロアルキル、CN、OH、C1-C5アルコキシ、およびハロゲンから選択され、同じ炭素上の2つのR2基が、ヘテロ原子を伴い、または伴わずに連結して、スピロ環式環系を形成してもよく、
R3は、H、CN、C1-C6アルキル、C3-C6シクロアルキルから選択され、
R4は、H、C1-C6アルキルから選択され、
R5は、H、C1-C6アルキル、C3-C6シクロアルキル、C1-C6-アルキル-NH2、C1-C6アルキルNH(C1-C6アルキル)、C1-C6アルキル-N(C1-C6アルキル)(C1-C6アルキル)、C1-C5アルキル-C1-C5アルコキシまたはC1-C6アルキル-ヘテロシクリル;から選択され、
R6は、H、C1-C5アルキル、C3-C6シクロアルキル、C1-C5-アルキル-C3-C6-シクロアルキル、C1-C5アルキル-C1-C5アルコキシ、C1-C5アルキル-OH、C1-C5アルキル-NH2、C1-C5アルキル-NH-C1-C5アルキル、およびC1-C5アルキル-N-(C1-C5アルキル)(C1-C5アルキル);から選択される)。 Compounds of formula (I) or derivatives thereof:
(In the formula,
X is N or CR3 ;
n is 0, 1 or 2;
m is 0, 1 or 2;
R 1 is COOR 6 , C 1 -C 5 alkyl-COOR 6 , bicycloalkyl, C 1 -C 5 -alkyl-heterocyclyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, C 3 - selected from C(O)C 1 -C 5 alkyl, C(O)C 3 -C 6 cycloalkyl, C(O)C 3 -C 6 heterocyclyl ;
Cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are C 1 -C 5 alkyl, C 1 -C 5 alkoxy, C 1 -C 5 alkyl-C 1 -C 5 alkoxy, CN, halogen, COOR 6 or C 1 optionally substituted with one or more groups selected from —C 5 -alkyl-COOR 6 ,
R 2 is H, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, CN, OH, C 1 -C 5 alkoxy, and two R groups on the same carbon, selected from halogen, may be joined with or without a heteroatom to form a spirocyclic ring system;
R 3 is selected from H, CN, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl;
R 4 is selected from H, C 1 -C 6 alkyl,
R 5 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 -alkyl-NH 2 , C 1 -C 6 alkylNH(C 1 -C 6 alkyl), C 1 —C 6 alkyl-N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), C 1 -C 5 alkyl-C 1 -C 5 alkoxy or C 1 -C 6 alkyl-heterocyclyl;
R 6 is H, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, C 1 -C 5 alkyl-C 1 -C 5 Alkoxy, C 1 -C 5 alkyl-OH, C 1 -C 5 alkyl-NH 2 , C 1 -C 5 alkyl-NH-C 1 -C 5 alkyl, and C 1 -C 5 alkyl-N-(C 1 -C 5 alkyl-N-(C 1 —C 5 alkyl) (C 1 -C 5 alkyl);).
(式中、
Xは、NまたはCR23であり、
nは、0、1または2であり、
mは、0、1または2であり、
R21は、COOR26、C1-C5アルキル-COOR26、ビシクロアルキル、C1-C5-アルキル-ヘテロシクリル、C1-C5-アルキル-C3-C6-シクロアルキル、C3-C6シクロアルキル、C(O)C1-C5アルキル、C(O)C3-C6シクロアルキル、C(O)C3-C6ヘテロシクリルから選択され、
シクロアルキル、ビシクロアルキル、ヘテロシクリル、およびアルキルは、C1-C5アルキル、C1-C5アルコキシ、C1-C5アルキル-C1-C5アルコキシ、CN、ハロゲン、COOR26、またはC1-C5-アルキル-COOR26から選択される1つまたは複数の基で置換されていてもよく、
R22は、H、C1-C5アルキル、C3-C6シクロアルキル、C1-C5-アルキル-C3-C6-シクロアルキル、CN、OH、C1-C5アルコキシ、ハロゲンから選択され、同じ炭素上の2つのR2基が、ヘテロ原子を伴い、または伴わずに連結して、スピロ環式環系を形成してもよく、
R23は、H、CN、C1-C6アルキル、C3-C6シクロアルキルから選択され、
R24は、H、C1-C6アルキルから選択され、
R25は、H、C1-C6アルキル、C3-C6シクロアルキル、C1-C6-アルキル-NH2、C1-C6アルキルNH(C1-C6アルキル)、C1-C6アルキル-N(C1-C6アルキル)(C1-C6アルキル)、C1-C5アルキル-C1-C5アルコキシまたはC1-C6アルキル-ヘテロシクリル;から選択され、
R26は、H、C1-C5アルキル、C3-C6シクロアルキル、C1-C5-アルキル-C3-C6-シクロアルキル、C1-C5アルキル-C1-C5アルコキシ、C1-C5アルキル-OH、C1-C5アルキル-NH2、C1-C5アルキル-NH-C1-C5アルキル、およびC1-C5アルキル-N-(C1-C5アルキル)(C1-C5アルキル);から選択される)。 A compound of formula (II) or a derivative thereof:
(In the formula,
X is N or CR23 ;
n is 0, 1 or 2;
m is 0, 1 or 2;
R 21 is COOR 26 , C 1 -C 5 alkyl-COOR 26 , bicycloalkyl, C 1 -C 5 -alkyl-heterocyclyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, C 3 - selected from C(O)C 1 -C 5 alkyl, C(O)C 3 -C 6 cycloalkyl, C(O)C 3 -C 6 heterocyclyl ;
Cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are C 1 -C 5 alkyl, C 1 -C 5 alkoxy, C 1 -C 5 alkyl-C 1 -C 5 alkoxy, CN, halogen, COOR 26 or C 1 optionally substituted with one or more groups selected from —C 5 -alkyl-COOR 26 ;
R 22 is H, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, CN, OH, C 1 -C 5 alkoxy, halogen and two R groups on the same carbon may be joined, with or without a heteroatom, to form a spirocyclic ring system,
R 23 is selected from H, CN, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl;
R 24 is selected from H, C 1 -C 6 alkyl,
R 25 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 -alkyl-NH 2 , C 1 -C 6 alkylNH(C 1 -C 6 alkyl), C 1 —C 6 alkyl-N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), C 1 -C 5 alkyl-C 1 -C 5 alkoxy or C 1 -C 6 alkyl-heterocyclyl;
R 26 is H, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, C 1 -C 5 alkyl-C 1 -C 5 Alkoxy, C 1 -C 5 alkyl-OH, C 1 -C 5 alkyl-NH 2 , C 1 -C 5 alkyl-NH-C 1 -C 5 alkyl, and C 1 -C 5 alkyl-N-(C 1 -C 5 alkyl-N-(C 1 —C 5 alkyl) (C 1 -C 5 alkyl);).
(式中、
Xは、CR33またはNであり、
nは、1または2であり、
nが1の場合、mは0、1または2であり、nが2の場合、mは1であり、
R31は、COOR36、C1-C5アルキル-COOR36、ビシクロアルキル、C1-C5-アルキル-ヘテロシクリル、C1-C5-アルキル-C3-C6-シクロアルキル、C3-C6シクロアルキル、C(O)C1-C5アルキル、C(O)C3-C6シクロアルキル、C(O)C3-C6ヘテロシクリルから選択され、シクロアルキル、ビシクロアルキル、ヘテロシクリル、およびアルキルは、C1-C5アルキル、C1-C5アルコキシ、C1-C5アルキル-C1-C5アルコキシ、CN、ハロゲン、COOR36、またはC1-C5-アルキル-COOR36から選択される1つまたは複数の基で置換されていてもよく、
R32は、H、C1-C5アルキル、C3-C6シクロアルキル、C1-C5-アルキル-C3-C6-シクロアルキルから選択され、
R33は、H、CN、C1-C6アルキル、C3-C6シクロアルキルから選択され、
R34は、H、C1-C6アルキルから選択され、
R35は、H、C1-C6アルキル、C3-C6シクロアルキル、C1-C6-アルキル-NH2、C1-C6アルキルNH(C1-C6アルキル)、C1-C6アルキル-N(C1-C6アルキル)(C1-C6アルキル)、C1-C5アルキル-C1-C5アルコキシから選択され、
R36は、H、C1-C5アルキル、C3-C6シクロアルキル、C1-C5-アルキル-C3-C6-シクロアルキル、C1-C5アルキル-C1-C5アルコキシ、C1-C5アルキル-OH、C1-C5アルキル-NH2、C1-C5アルキル-NH-C1-C5アルキル、およびC1-C5アルキル-N-(C1-C5アルキル)(C1-C5アルキル);から選択される)。 A compound of formula (III) or a derivative thereof:
(In the formula,
X is CR33 or N;
n is 1 or 2,
when n is 1, m is 0, 1 or 2; when n is 2, m is 1;
R 31 is COOR 36 , C 1 -C 5 alkyl-COOR 36 , bicycloalkyl, C 1 -C 5 -alkyl-heterocyclyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, C 3 - C6 cycloalkyl, C(O)C1 - C5 alkyl, C ( O)C3 - C6 cycloalkyl , C ( O)C3 - C6 heterocyclyl, cycloalkyl, bicycloalkyl, heterocyclyl, and alkyl is C 1 -C 5 alkyl, C 1 -C 5 alkoxy, C 1 -C 5 alkyl-C 1 -C 5 alkoxy, CN, halogen, COOR 36 or C 1 -C 5 -alkyl-COOR 36 optionally substituted with one or more groups selected from
R 32 is selected from H, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl,
R 33 is selected from H, CN, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl;
R 34 is selected from H, C 1 -C 6 alkyl,
R 35 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 -alkyl-NH 2 , C 1 -C 6 alkylNH(C 1 -C 6 alkyl), C 1 selected from —C 6 alkyl-N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), C 1 -C 5 alkyl-C 1 -C 5 alkoxy;
R 36 is H, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, C 1 -C 5 alkyl-C 1 -C 5 Alkoxy, C 1 -C 5 alkyl-OH, C 1 -C 5 alkyl-NH 2 , C 1 -C 5 alkyl-NH-C 1 -C 5 alkyl, and C 1 -C 5 alkyl-N-(C 1 -C 5 alkyl-N-(C 1 —C 5 alkyl) (C 1 -C 5 alkyl);).
(式中、
Xは、CR43またはNであり、
nは、1または2であり、
nが1の場合、mは0、1または2であり、nが2の場合、mは1であり、
R41は、COOR46、C1-C5アルキル-COOR46、ビシクロアルキル、C1-C5-アルキル-ヘテロシクリル、C1-C5-アルキル-C3-C6-シクロアルキル、C3-C6シクロアルキル、C(O)C1-C5アルキル、C(O)C3-C6シクロアルキル、C(O)C3-C6ヘテロシクリルから選択され、シクロアルキル、ビシクロアルキル、ヘテロシクリル、およびアルキルは、C1-C5アルキル、C1-C5アルコキシ、C1-C5アルキル-C1-C5アルコキシ、CN、ハロゲン、COOR46、またはC1-C5-アルキル-COOR46から選択される1つまたは複数の基で置換されていてもよく、
R42は、H、C1-C5アルキル、C3-C6シクロアルキル、C1-C5-アルキル-C3-C6-シクロアルキルから選択され、
R43は、H、CN、C1-C6アルキル、C3-C6シクロアルキルから選択され、
R44は、H、C1-C6アルキルから選択され、
R45は、H、C1-C6アルキル、C3-C6シクロアルキル、C1-C6-アルキル-NH2、C1-C6アルキルNH(C1-C6アルキル)、C1-C6アルキル-N(C1-C6アルキル)(C1-C6アルキル)、C1-C5アルキル-C1-C5アルコキシ;から選択され、
R46は、H、C1-C5アルキル、C3-C6シクロアルキル、C1-C5-アルキル-C3-C6-シクロアルキル、C1-C5アルキル-C1-C5アルコキシ、C1-C5アルキル-OH、C1-C5アルキル-NH2、C1-C5アルキル-NH-C1-C5アルキル、およびC1-C5アルキル-N-(C1-C5アルキル)(C1-C5アルキル);から選択される)。 A compound of formula (IV) or a derivative thereof:
(In the formula,
X is CR 43 or N;
n is 1 or 2,
when n is 1, m is 0, 1 or 2; when n is 2, m is 1;
R 41 is COOR 46 , C 1 -C 5 alkyl-COOR 46 , bicycloalkyl, C 1 -C 5 -alkyl-heterocyclyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, C 3 - C6 cycloalkyl, C(O)C1 - C5 alkyl, C ( O)C3 - C6 cycloalkyl , C ( O)C3 - C6 heterocyclyl, cycloalkyl, bicycloalkyl, heterocyclyl, and alkyl is C 1 -C 5 alkyl, C 1 -C 5 alkoxy, C 1 -C 5 alkyl-C 1 -C 5 alkoxy, CN, halogen, COOR 46 or C 1 -C 5 -alkyl-COOR 46 optionally substituted with one or more groups selected from
R 42 is selected from H, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl,
R 43 is selected from H, CN, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl;
R 44 is selected from H, C 1 -C 6 alkyl,
R 45 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 -alkyl-NH2, C 1 -C 6 alkylNH(C 1 -C 6 alkyl), C 1 - selected from C 6 alkyl-N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), C 1 -C 5 alkyl-C 1 -C 5 alkoxy;
R 46 is H, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 5 -alkyl-C 3 -C 6 -cycloalkyl, C 1 -C 5 alkyl-C 1 -C 5 Alkoxy, C 1 -C 5 alkyl-OH, C 1 -C 5 alkyl-NH 2 , C 1 -C 5 alkyl-NH-C 1 -C 5 alkyl, and C 1 -C 5 alkyl-N-(C 1 -C 5 alkyl-N-(C 1 —C 5 alkyl) (C 1 -C 5 alkyl);).
から選択される、請求項1に記載の化合物。 a compound, or a derivative thereof,
2. The compound of claim 1, selected from
から選択される、請求項3に記載の化合物。 a compound, or a derivative thereof,
4. The compound of claim 3, selected from
から選択される式(I)の化合物、またはその誘導体である、請求項8に記載の医薬組成物。 one or more compounds
9. The pharmaceutical composition according to claim 8, which is a compound of formula (I) selected from or a derivative thereof.
から選択される式(III)の化合物またはその誘導体である、請求項8に記載の医薬組成物。
9. The pharmaceutical composition according to claim 8, which is a compound of formula (III) selected from or a derivative thereof.
から選択される式(I)の化合物またはその誘導体である、請求項12に記載の医薬組成物。 one or more compounds are
13. The pharmaceutical composition according to claim 12 , which is a compound of formula (I) selected from or a derivative thereof.
から選択される式(III)の化合物またはその誘導体である、請求項12に記載の医薬組成物。 one or more compounds are
13. The pharmaceutical composition according to claim 12 , which is a compound of formula (III) selected from or a derivative thereof.
(1-((2S,5R)-5-((5-(シクロブタンカルボニル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-メチルピペリジン-1-イル)プロパ-2-エン-1-オン)
である、請求項1に記載の化合物またはその誘導体。
(1-((2S,5R)-5-((5-(cyclobutanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)propane -2-en-1-on)
The compound or derivative thereof according to claim 1, wherein
(1-((2S,5R)-5-((5-(シクロプロピルメチル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-メチルピペリジン-1-イル)プロパ-2-エン-1-オン)
である、請求項1に記載の化合物またはその誘導体。
(1-((2S,5R)-5-((5-(cyclopropylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl) propa-2-en-1-one)
The compound or derivative thereof according to claim 1, wherein
(1-((2S,5R)-5-((5-((R)-2,2-ジフルオロシクロプロピル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-メチルピペリジン-1-イル)プロパ-2-エン-1-オン)
である、請求項1に記載の化合物またはその誘導体。
(1-((2S,5R)-5-((5-((R)-2,2-difluorocyclopropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2 -methylpiperidin-1-yl)prop-2-en-1-one)
2. The compound or derivative thereof according to claim 1, wherein
((E)-1-((2S,5R)-5-((5-((R)-2,2-ジフルオロシクロプロピル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-メチルピペリジン-1-イル)-4-(ジメチルアミノ)ブタ-2-エン-1-オン)
である、請求項1に記載の化合物またはその誘導体。
((E)-1-((2S,5R)-5-((5-((R)-2,2-difluorocyclopropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl) amino)-2-methylpiperidin-1-yl)-4-(dimethylamino)but-2-en-1-one)
The compound or derivative thereof according to claim 1, wherein
(1-((2S,5R)-5-((5-((3S,5S)-1,1-ジフルオロスピロ[2.4]ヘプタン-5-イル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-メチルピペリジン-1-イル)プロパ-2-エン-1-オン)、
である、請求項1に記載の化合物またはその誘導体。
(1-((2S,5R)-5-((5-((3S,5S)-1,1-difluorospiro[2.4]heptan-5-yl)-7H-pyrrolo[2,3-d]pyrimidine -4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one),
The compound or derivative thereof according to claim 1, wherein
(1-((2S,5R)-5-((5-(1-ヒドロキシシクロブチル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-メチルピペリジン-1-イル)プロパ-2-エン-1-オン)
である、請求項1に記載の化合物またはその誘導体。
(1-((2S,5R)-5-((5-(1-hydroxycyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidine-1- yl)prop-2-en-1-one)
The compound or derivative thereof according to claim 1, wherein
(1-((2S,5R)-5-((5-(((R)-2,2-ジフルオロシクロプロピル)メチル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-メチルピペリジン-1-イル)プロパ-2-エン-1-オン)
である、請求項1に記載の化合物またはその誘導体。
(1-((2S,5R)-5-((5-(((R)-2,2-difluorocyclopropyl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino )-2-methylpiperidin-1-yl)prop-2-en-1-one)
The compound or derivative thereof according to claim 1, wherein
(1-((2S,5R)-5-((5-((3R,5R)-1,1-ジフルオロスピロ[2.4]ヘプタン-5-イル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-メチルピペリジン-1-イル)プロパ-2-エン-1-オン)
である、請求項1に記載の化合物またはその誘導体。
(1-((2S,5R)-5-((5-((3R,5R)-1,1-difluorospiro[2.4]heptan-5-yl)-7H-pyrrolo[2,3-d]pyrimidine) -4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one)
The compound or derivative thereof according to claim 1, wherein
(1-((2S,5S)-5-((5-((R)-2,2-ジフルオロシクロプロピル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-イソプロピルピペリジン-1-イル)プロパ-2-エン-1-オン)
である、請求項1に記載の化合物またはその誘導体。
(1-((2S,5S)-5-((5-((R)-2,2-difluorocyclopropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2 -isopropylpiperidin-1-yl)prop-2-en-1-one)
The compound or derivative thereof according to claim 1, wherein
(1-((2S,5R)-5-((5-((S)-2,2-ジフルオロシクロプロピル)-7H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ)-2-エチルピペリジン-1-イル)プロパ-2-エン-1-オン)
である、請求項1に記載の化合物またはその誘導体。
(1-((2S,5R)-5-((5-((S)-2,2-difluorocyclopropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2 -ethylpiperidin-1-yl)prop-2-en-1-one)
The compound or derivative thereof according to claim 1, wherein
(I)
(式中、
Xは、Nであり、
nは、2であり、
mは、1であり、
R1は、C3-C6シクロアルキルであり、シクロアルキルはC1-C5アルキルおよびハロゲンから選択される1つまたは複数の基で置換されており、
R2は、C1-C5アルキル、であり、
R3は、HまたはC1-C6アルキルであり
R4は、Hであり、
R5は、H、C1-C6アルキルまたはC1-C6アルキルNH(C1-C6アルキル)から選択される)。 A compound of formula (I) or a derivative thereof:
(I)
(In the formula,
X is N;
n is 2;
m is 1;
R 1 is C 3 -C 6 cycloalkyl, which cycloalkyl is substituted with one or more groups selected from C 1 -C 5 alkyl and halogen;
R 2 is C 1 -C 5 alkyl,
R 3 is H or C 1 -C 6 alkyl and R 4 is H,
R 5 is selected from H, C 1 -C 6 alkyl or C 1 -C 6 alkylNH(C 1 -C 6 alkyl)).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862717400P | 2018-08-10 | 2018-08-10 | |
US62/717,400 | 2018-08-10 | ||
PCT/US2019/046182 WO2020033955A1 (en) | 2018-08-10 | 2019-08-12 | Pyrrolopyrimidine itk inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021534244A JP2021534244A (en) | 2021-12-09 |
JPWO2020033955A5 true JPWO2020033955A5 (en) | 2022-08-29 |
Family
ID=69405523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021531626A Pending JP2021534244A (en) | 2018-08-10 | 2019-08-12 | Pyrrolopyrimidine ITK inhibitor |
Country Status (13)
Country | Link |
---|---|
US (2) | US11021482B2 (en) |
EP (1) | EP3833350A4 (en) |
JP (1) | JP2021534244A (en) |
KR (1) | KR20210044822A (en) |
CN (1) | CN112823005A (en) |
AU (1) | AU2019317625A1 (en) |
BR (1) | BR112021002479A2 (en) |
CA (1) | CA3109192A1 (en) |
IL (1) | IL280593A (en) |
MX (1) | MX2021001558A (en) |
PH (1) | PH12021550187A1 (en) |
SG (1) | SG11202100525SA (en) |
WO (1) | WO2020033955A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190043437A (en) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | Heterocylic compound as a protein kinase inhibitor |
EP3710431A4 (en) | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
CN112823005A (en) | 2018-08-10 | 2021-05-18 | 阿克拉瑞斯治疗股份有限公司 | Pyrrolopyrimidine ITK inhibitors |
EP3962897A4 (en) | 2019-05-02 | 2022-12-14 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as jak inhibitors |
JP2022550463A (en) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | Genetic engineering of fungi to modulate tryptamine expression |
JP2023528239A (en) * | 2020-05-14 | 2023-07-04 | テラバンス バイオファーマ アールアンドディー アイピー リミテッド ライアビリティ カンパニー | Administration of intestinal selective JAK3 inhibitor |
KR102560138B1 (en) * | 2020-06-15 | 2023-07-27 | 경북대학교 산학협력단 | Use for regulating neuroinflammation of glial kinases selected by multiplexed kinome-wide siRNA screening for glial cell behaviors |
CN114887080B (en) * | 2020-12-08 | 2023-10-31 | 深圳瑞吉生物科技有限公司 | Immunosuppressant of mRNA dosage form and application thereof in preparing tumor therapeutic drug |
CN113350346B (en) * | 2021-06-01 | 2023-06-27 | 广西医科大学第一附属医院 | Use of vincristine in preventing or treating myocardial fibrosis |
KR20230019801A (en) * | 2021-08-02 | 2023-02-09 | 한국화학연구원 | Novel pyrrlopyrimidine derivatives compound, preparing method thereof, and pharmaceutical composition for preventing or treating metabolic liver related diseases containing the same as an active ingredient |
CN113571191A (en) * | 2021-08-31 | 2021-10-29 | 复旦大学附属中山医院 | Method for predicting risk of MACE occurrence associated with immune checkpoint inhibitors |
WO2023110843A1 (en) * | 2021-12-15 | 2023-06-22 | Almirall, S.A. | Heterobicyclic derivatives as itk inhibitors |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1061036C (en) | 1993-11-30 | 2001-01-24 | G·D·瑟尔公司 | Substituted pyrazolyl benzenesulfonamides for treating inflammation |
PA8474101A1 (en) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
WO2000000202A1 (en) | 1998-06-30 | 2000-01-06 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
SE0301372D0 (en) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
AR054416A1 (en) | 2004-12-22 | 2007-06-27 | Incyte Corp | PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS. |
AU2006251623A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
KR20080026654A (en) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | Heterocyclic janus kinase 3 inhibitors |
EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
ES2612196T3 (en) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
KR20090106604A (en) | 2007-01-12 | 2009-10-09 | 아스텔라스세이야쿠 가부시키가이샤 | Condensed pyridine compound |
EP2173752B2 (en) | 2007-06-13 | 2022-07-13 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CL2009001884A1 (en) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye. |
TWI484962B (en) | 2009-05-22 | 2015-05-21 | Incyte Corp | 3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)octane-or heptane-nitrile as jak inhibitors |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9273028B2 (en) | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
CN103732597B (en) | 2011-08-12 | 2016-08-17 | 日产化学工业株式会社 | Tricyclic heterocyclic compounds and JAK inhibitor |
NZ630178A (en) | 2012-09-07 | 2017-06-30 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
MY187446A (en) | 2013-12-05 | 2021-09-22 | Pfizer | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
AP2016009562A0 (en) | 2014-05-14 | 2016-11-30 | Pfizer | Pyrazolopyridines and pyrazolopyrimidines |
CN105777756B (en) * | 2014-07-02 | 2019-03-01 | 广东东阳光药业有限公司 | Heteroaryl compound and its application in drug |
CN105712998B (en) * | 2014-12-05 | 2019-12-13 | 上海润诺生物科技有限公司 | Azaindole derivatives, preparation method and medical application thereof |
MX2017009571A (en) * | 2015-01-23 | 2018-09-27 | Aclaris Therapeutics Inc | Heterocyclic itk inhibitors for treating inflammation and cancer. |
JP6761815B2 (en) | 2015-05-01 | 2020-09-30 | ファイザー・インク | Piroro [2,3-d] pyrimidinyl, piroro [2,3-b] pyrazinyl, piroro [2,3-b] pyridinylacrylamide, and epoxides thereof |
CN108137603B (en) | 2015-12-11 | 2019-10-18 | 四川科伦博泰生物医药股份有限公司 | Azetidine derivatives, preparation method and the usage |
AU2017287762C1 (en) * | 2016-06-30 | 2020-04-23 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
CA3034010A1 (en) | 2016-08-24 | 2018-03-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
EP3710431A4 (en) | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
CN112823005A (en) | 2018-08-10 | 2021-05-18 | 阿克拉瑞斯治疗股份有限公司 | Pyrrolopyrimidine ITK inhibitors |
EP3962897A4 (en) | 2019-05-02 | 2022-12-14 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as jak inhibitors |
JP2022545568A (en) | 2019-06-10 | 2022-10-27 | インサイト・コーポレイション | Topical treatment of vitiligo with JAK inhibitors |
-
2019
- 2019-08-12 CN CN201980066579.2A patent/CN112823005A/en active Pending
- 2019-08-12 CA CA3109192A patent/CA3109192A1/en active Pending
- 2019-08-12 US US16/538,354 patent/US11021482B2/en active Active
- 2019-08-12 JP JP2021531626A patent/JP2021534244A/en active Pending
- 2019-08-12 BR BR112021002479-4A patent/BR112021002479A2/en unknown
- 2019-08-12 SG SG11202100525SA patent/SG11202100525SA/en unknown
- 2019-08-12 WO PCT/US2019/046182 patent/WO2020033955A1/en unknown
- 2019-08-12 EP EP19846283.0A patent/EP3833350A4/en active Pending
- 2019-08-12 KR KR1020217007377A patent/KR20210044822A/en active Search and Examination
- 2019-08-12 MX MX2021001558A patent/MX2021001558A/en unknown
- 2019-08-12 AU AU2019317625A patent/AU2019317625A1/en active Pending
-
2021
- 2021-01-25 PH PH12021550187A patent/PH12021550187A1/en unknown
- 2021-02-02 IL IL280593A patent/IL280593A/en unknown
- 2021-04-21 US US17/236,531 patent/US11820775B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3183247T3 (en) | Aminopyrimidinyl compounds as JAK inhibitors | |
JPWO2020033955A5 (en) | ||
AU2009246402B2 (en) | Pyrrolopyridines as kinase inhibitors | |
JP5782042B2 (en) | Pyrimidine compounds as delta opioid receptor modulators | |
CN109311896A (en) | Pyrazolopyrimidine derivative is as kinase inhibitor | |
CA3026578A1 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
EA031476B1 (en) | 4'-substituted nucleoside inhibitors of reverse transcriptase | |
AU2017378943A1 (en) | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | |
JP2024019402A (en) | Substituted pyrrolopyridine jak inhibitors and methods of making and using the same | |
JP2019514903A5 (en) | ||
CN110573504A (en) | heterocyclic amides as kinase inhibitors | |
JP2020525513A (en) | N-(3-(2-(4-chlorophenoxy)acetamidobicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1 as an ATF4 inhibitor for treating cancer and other diseases -Carboxamide derivatives and related compounds | |
WO2008124085A2 (en) | Methods of using combinations of mek and jak-2 inhibitors | |
WO2008033999A2 (en) | Kinase inhibitors useful for the treatment of proliferative diseases | |
BR112021002479A2 (en) | compound, pharmaceutical composition, method of inhibiting the activity of itk or jak3 in a population of cells, method of treating an itk or jak3 mediated disorder in an individual in need thereof, and use of a compound | |
JP2007515489A5 (en) | ||
TW202115034A (en) | Heterocyclic compounds for mediating tyrosine kinase 2 activity | |
CA3181790A1 (en) | Amidopyrimidone derivatives | |
JP2021500380A (en) | A novel pyrazolo-pyrrolo-pyrimidine-dione derivative as a P2X3 inhibitor | |
JPWO2021022186A5 (en) | ||
CN114008044A (en) | Pyridyl or pyrimidinyl MTOR kinase inhibitors | |
CN112689636A (en) | Novel heteroatom aromatic amide derivative and drug containing the same | |
TW201141840A (en) | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists | |
JPWO2020223728A5 (en) | ||
JP2023554596A (en) | Compounds, compositions and methods |